AstraZeneca’s Tagrisso with the addition of pemetrexed and platinum-based chemotherapy has been recommended for approval in the European Union for first-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, or NSCLC, whose tumours have exon 19 deletions or exon 21 mutations, the company announced.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Fusion Pharmaceuticals receives final court order approving AstraZeneca deal
- PayPal upgraded, UiPath downgraded: Wall Street’s top analyst calls
- AstraZeneca price target raised to $85 from $80 at Argus
- Compugen to receive $5M milestone payment from AstraZeneca
- AstraZeneca initiated with a Buy at Goldman Sachs